VWM
TRIL

Vigilare Wealth Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Vigilare Wealth Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-59,215
Closed -$574K – 224
2021
Q2 		$574K Buy
59,215
+6,635
+13% +$62.4K 0.35% 82
2021
Q1 		$565K Buy
52,580
+18,615
+55% +$230K 0.4% 69
2020
Q4 		$500K Buy
33,965
+13,245
+64% +$191K 0.47% 52
2020
Q3 		$294K Sell
20,720
-5,380
-21% -$53.6K 0.31% 78
2020
Q2 		$211K Buy
+26,100
New +$161K 0.21% 110

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Vigilare Wealth Management's TRIL Position: Q3 2021 in Review

Vigilare Wealth Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 59,215 shares — an estimated $574K sold.

Vigilare Wealth Management first reported a position in TRIL in Q2 2020 and held it in 5 quarters. The position peaked at $574K in Q2 2021. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Vigilare Wealth Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Vigilare Wealth Management sold 59,215 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $574K.
  • Vigilare Wealth Management first reported a position in Trillium Therapeutics Inc. in Q2 2020 and held it in 5 quarters.
  • Vigilare Wealth Management's Trillium Therapeutics Inc. position peaked at $574K in Q2 2021.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Vigilare Wealth Management's 13F filing for Q3 2021, filed 19 Oct 2021.